Study of a new treatment for newly diagnosed acute lymphoblastic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is testing how well a new treatment works for adults who have just been diagnosed with acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow. It aims to see if the treatment is safe and effective in helping you reach remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been newly diagnosed with acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow, based on standard tests.
- You are able to take care of yourself (ECOG score 0-2).
- Your liver, kidney, and heart function are within safe limits (doctor will verify).
- If you are of childbearing age, you agree to use effective birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
This Phase 1 study looks at a treatment approach for people newly diagnosed with Philadelphia-negative B- or T-cell acute lymphoblastic leukemia (ALL) after completing a specific chemotherapy course called Hyper-CVAD 1A. It aims to see if the treatment can be given safely and how well it may work for this type of leukemia.
This early-phase trial tests lisaftoclax, alone or with other medicines, in people whose acute leukemia has returned or did not respond to prior treatment. It aims to find out how well the treatment works and how safe it is, especially for patients who may not be able to take standard chemotherapy.
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
This study tests three different chemotherapy regimens (LDA, LHAA, and DA) in adults aged 18–65 with newly diagnosed acute myeloid leukemia (AML, a blood cancer). The goal is to find which approach works best and is safest for patients fit enough for intensive treatment.
This trial tests a new drug called lisatoclax added to the usual chemotherapy and antibody treatment for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL). The goal is to see if adding this drug helps the standard treatment work better.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.